CahnP, MaderoJS, ArribasJR, et al.: Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet, 2019; 393:143–155.
2.
CicculloA, BaldinG, CossuMV, et al.: Dolutegravir plus lamivudine as first-line regimen in a Multicenter Cohort of HIV-1-infected patients: Preliminary data from clinical practice. AIDS Res Hum Retroviruses, 2020; 36:4–5.
3.
HurtCB, SebastianJ, HicksCB, EronJJ: Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012. Clin Infect Dis, 2014; 58:423–431.
4.
LaananiM, GhosnJ, EssatA, et al.: Impact of the timing of initiation of antiretroviral therapy during primary HIV-1 infection on the decay of cell-associated HIV-DNA. Clin Infect Dis, 2015; 60:1715–1721.
